Ocular Therapeutix, Inc.
OCUL
$11.34
$0.090.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.54M | 13.46M | 10.70M | 17.08M | 15.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.54M | 13.46M | 10.70M | 17.08M | 15.43M |
| Cost of Revenue | 54.13M | 53.03M | 44.12M | 42.22M | 38.62M |
| Gross Profit | -39.59M | -39.57M | -33.42M | -25.14M | -23.19M |
| SG&A Expenses | 29.11M | 28.08M | 30.50M | 38.54M | 22.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.24M | 81.10M | 74.62M | 80.76M | 61.42M |
| Operating Income | -68.70M | -67.64M | -63.92M | -63.68M | -46.00M |
| Income Before Tax | -69.42M | -67.81M | -64.05M | -48.39M | -36.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.42M | -67.81M | -64.05M | -48.39M | -36.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.42M | -67.81M | -64.05M | -48.39M | -36.49M |
| EBIT | -68.70M | -67.64M | -63.92M | -63.68M | -46.00M |
| EBITDA | -67.63M | -66.62M | -62.94M | -62.73M | -45.04M |
| EPS Basic | -0.38 | -0.39 | -0.38 | -0.29 | -0.22 |
| Normalized Basic EPS | -0.24 | -0.25 | -0.24 | -0.23 | -0.14 |
| EPS Diluted | -0.38 | -0.39 | -0.38 | -0.29 | -0.22 |
| Normalized Diluted EPS | -0.24 | -0.25 | -0.24 | -0.23 | -0.14 |
| Average Basic Shares Outstanding | 183.92M | 172.59M | 169.40M | 168.02M | 166.99M |
| Average Diluted Shares Outstanding | 183.92M | 172.59M | 169.40M | 168.02M | 166.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |